Orchard Therapeutics (ORTX) PT Raised to $13 at Goldman Sachs, Following Clinical Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ORTX Hot Sheet
Price: $16.70 --0%
Rating Summary:
6 Buy, 3 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
6 Buy, 3 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
Goldman Sachs analyst Graig Suvannavejh raised the price target on Orchard Therapeutics (NASDAQ: ORTX) to $13.00 (from $9.00) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Clear Secure Inc (YOU) PT Raised to $80 at Goldman Sachs
- Procore Technologies, Inc (PCOR) PT Raised to $90 at BTIG
- First Industrial Realty Trust (FR) PT Lowered to $62 at Truist Securities
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
